secwatch.observer — SEC 8-K summary
======================================

Issuer:     Serina Therapeutics, Inc. (SER)
CIK:        0001708599
Form:       8-K
Filed at:   2023-11-17T23:59:59+00:00
Accession:  0001493152-23-041874
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AgeX draws $500k from secured note; Serina licenses POZ polymer tech to Pfizer
------------------------------------------------------------------------------

- AgeX drew $500k under Amended Secured Convertible Promissory Note with Juvenescence; maturity Feb 14, 2024.
- Serina Therapeutics entered non-exclusive license with Pfizer for POZ polymer technology for LNP formulations.
- License agreement is potential milestone for Serina, which is merging with AgeX (S-4 filed Nov 14, 2023).
- AgeX's merger with Serina remains subject to stockholder and SEC approvals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708599/000149315223041874/0001493152-23-041874-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708599/000149315223041874/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-041874

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer